— Developed by world-renowned neuroscientist Professor Adrian Owen,Creyos helps providers detect cognitive impairment through a scientifically validated brain health assessment platform grounded in decades of neuroscience and real-world research
— With protocols to support the clinical evaluation of patients for cognitive impairment associated with conditions such as dementia, the addition of session notes translates objective assessment results into structured documentation that can assist with clinical decision-making, appropriate referrals, accurate coding, and timely intervention.
— Used in more than 1,000 clinics and cited in over 400 peer-reviewed publications, theCreyos platform brings scientific validation into everyday care. Features like automated session notes and EHR integration help providers take faster, more consistent action on cognitive health data in primary care.
Creyos, the digital platform reshaping brain health assessment in clinical care, has expanded its Session Notes feature to support structured assessment protocols commonly used in the evaluation of cognitive function related to conditions like dementia. The addition of session notes to protocols is designed to help close the gap in detection by turning cognitive screening and assessment results into structured, clinically relevant, documentation. Providers can use these notes to support referrals, billing, and care planning, all within the workflows they already use. Each note pulls in key insights from the patient's cognitive performance and populates a structured, editable summary. This report can be reviewed and inserted into the EHR in seconds, reducing documentation time, providing objective proof for clinical decisions, and supporting consistent next steps in care.
https://mma.prnewswire.com/media/2683996/Creyos_Full_Colours_Logo.jpg
This enhancement comes at a pivotal moment, as the aging U.S. population drives a surge in dementia-related challenges. Primary care providers face mounting pressure to detect cognitive decline early, especially with CMS requiring cognitive screening during Medicare Annual Wellness Visits. Yet the broader care infrastructure has not kept pace. Value-based care models increasingly reward timely, accurate detection, but withlimited specialist availability, primary care teams often lack the time, tools, and support needed to respond effectively. For patients and families, this gap can mean delayed diagnoses, missed treatment opportunities, and long waits for clarity.
“We expanded our Session Notes feature in direct response to what we heard from primary care teams. They're facing tight visit times and rising cognitive health concerns with no easy way to document it all,” said Faraz Shafaghi, Chief Product Officer at Creyos. “We designed this feature to help providers turn cognitive data into immediate next steps. It gives clinicians practical support and is a leap forward in making brain health operational in the reality of primary care.”
“Measuring cognitive health in patients 65 and older is essential for early detection and timely intervention,” said Dr. Anthony Zizza, a geriatrician and consultant specializing in dementia and geriatric care who reviewed the Session Notes feature. “When providers can identify issues sooner, they're able to personalize care, connect patients with the right support, and help preserve independence and quality of life. However, primary care teams are already stretched thin; so evidence-based tools that also support team-based workflows are crucial to ensure cognitive health does not fall through the cracks in such a demanding clinical environment.”
For full risk-bearing organizations managing Medicare Advantage populations, timely identification and accurate documentation of cognitive impairment is essential for both clinical care and for ensuring records hold up to review. When a dementia diagnosis is clearly documented and appropriately coded, it supports better care planning, smoother coordination, proper reimbursement, and confidence in compliance. Still, many providers don't have the right tools to assess and document cognitive issues consistently or efficiently.
“We're seeing more and more healthcare leaders realize that cognitive decline isn't just a medical issue-it's a documentation challenge, too,” said Marc Lipton, CEO of Creyos. “Clinicians want to do the right thing, but they're stretched thin. That's why we built Session Notes right into the Creyos platform. Now, providers can use our screening and assessment tools to catch early signs of dementia-and at the same time, generate clear, structured records that support better care while still fitting into existing workflows.”
Built on decades of neuroscience research and used across neurology, mental health, and senior care settings, the Creyos platform enables early detection and monitoring for a range of cognitive and behavioral conditions. The platform is grounded in the pioneering work of Professor Adrian Owen, a globally recognized neuroscientist, Chief Scientific Officer, and co-founder of Creyos. His research has shaped how the scientific and medical community understands cognition, consciousness, and early decline and is the scientific bedrock guiding Creyos's ongoing innovation. Validated across diverse populations, the platform supports a wide range of clinical needs, from dementia screening in senior care to assessment for markers linked to mental and behavioral health conditions.
Session Notes are now available on screening protocols for cognitive concerns such as dementia and attention disorders. Visit www.creyos.com for details.
About CreyosCreyos, formerly known as Cambridge Brain Sciences, is a pioneering healthcare technology company dedicated to transforming how healthcare providers assess and manage patient brain health. Supporting clinicians and health systems worldwide, the Creyos platform includes objective online tasks, digital behavioral health screeners, and condition-specific assessments that deliver actionable insights, promote early intervention, and enable evidence-based clinical decisions for various cognitive and behavioral health conditions, including dementia, ADHD, depression, anxiety, and others. Backed by 30 years of research and a normative database of over 85,000 participants, the FDA-registered Creyos platform has been published in over 400 peer reviewed studies and is recognized as a scientifically-validated solution for measuring and monitoring patient brain health. For more information about Creyos visit www.creyos.com.
Media Contactcreyos@hermespr.co
https://c212.net/c/img/favicon.png?sn=NY46114&sd=2025-08-07
View original content to download multimedia:https://www.prnewswire.com/news-releases/creyos-expands-session-notes-to-turn-cognitive-health-testing-into-timely-clinical-action-302523708.html
SOURCE Creyos
https://rt.newswire.ca/rt.gif?NewsItemId=NY46114&Transmission_Id=202508070800PR_NEWS_USPR_____NY46114&DateId=20250807